Dynavax Technologies Corporation provided financial guidance for the full year 2023. For the year, the company expects HEPLISAV-B net product revenue between approximately $165 - $185 million.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
12.25 USD | -0.57% | +8.26% | -10.94% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-10.94% | 1.61B | |
+15.46% | 121B | |
+13.56% | 107B | |
-4.67% | 24.82B | |
+1.51% | 22.48B | |
-9.86% | 18.32B | |
-42.28% | 16.33B | |
-16.08% | 15.31B | |
+4.08% | 14.08B | |
+26.22% | 11.74B |
- Stock Market
- Equities
- DVAX Stock
- News Dynavax Technologies Corporation
- Dynavax Technologies Corporation Provides Financial Guidance for the Full Year 2023